IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
IgA nephropathy
IgA nephropathy diagnosed through renal biopsy
When screening, urine protein should be ≥0.5g/gCr and 20mL/min/1.73m²≤eGFR<60mL/min/1.73m²
Age≥18years old
Kidney diseases other than IgA nephropathy, as well as primary and secondary nephrotic syndrome
After examination by the researchers, it was determined that the subjects had diseases that were not suitable for participation in this study, such as life-threatening conditions (such as catastrophic antiphospholipid syndrome, acute severe renal failure, and acute severe central nervous system disease manifestations)
Serious complications unrelated to IgA nephropathy
Use or increase the dosage of corticosteroids, immunosuppressants, biologics (including but not limited to CD20 monoclonal antibodies, taceptil, etc.), anticoagulants (warfarin), and n-3 fatty acids (fish oil) for the drug treatment of IgA nephropathy within 3 months